Back to top
more

Adicet Bio (ACET)

(Delayed Data from NSDQ)

$1.05 USD

1.05
947,144

-0.09 (-7.89%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $1.06 +0.01 (0.95%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Viatris' (VTRS) Generic Declines in Q4, Yupleri Sales Rise

by Zacks Equity Research

Viatris (VTRS) stock down after posting weaker-than-expected results from its generics business. Nevertheless, the guidance for 2024 looks encouraging.

Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Amarin's (AMRN) fourth-quarter 2023 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year.

Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus

by Zacks Equity Research

Xenon (XENE) reports mixed fourth-quarter 2023 financial results, wherein earnings beat estimates but revenues missed the same. Its development programs for XEN1101 in epilepsy and MDD are progressing well.

Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues

by Zacks Equity Research

Pacira (PCRX) reports fourth-quarter 2023 results, wherein earnings match and revenues beat estimates, driven by strong Exparel sales.

Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys.

Catalyst (CPRX) Q4 Earnings & Sales Beat Estimates, Stock Up

by Zacks Equity Research

Catalyst (CPRX) reports encouraging fourth-quarter results, driven by Firdapse and Fycompa sales. The stock gains in the pre-market session.

Jazz (JAZZ) Q3 Earnings Lag, Revenues in Line With Estimates

by Zacks Equity Research

Jazz's (JAZZ) fourth-quarter earnings miss estimates while sales meet the mark. Shares drop 1.5% post the announcement.

Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates

by Zacks Equity Research

Iovance (IOVA) reports dismal earnings in the fourth quarter. Management is in the process of commercially launching the recently approved melanoma drug Amtagvi in the United States.

Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up

by Zacks Equity Research

Editas (EDIT) reports better-than-expected fourth-quarter 2023 results as both earnings and revenues beat estimates, driven by collaboration revenues received from Vertex. The stock gains 25%.

Viatris' (VTRS) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Viatris (VTRS) reports lower-than-expected fourth-quarter financial results, as both earnings and sales miss estimates. Stock declines in pre-market.

Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Perrigo (PRGO) Q4 Earnings Top, Sales Lag Estimates, Misses View

by Zacks Equity Research

Perrigo (PRGO) reports mixed fourth-quarter 2023 results. Management issues fresh financial outlook for 2024, which were below our expectations. Stock price drops 10% after this announcement.

Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4

by Zacks Equity Research

Rocket Pharmaceuticals' (RCKT) fourth-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.

Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y

by Zacks Equity Research

Fate Therapeutics (FATE) reports encouraging fourth-quarter results as loss narrows year over year due to lower operating expenses.

BioMarin (BMRN) Posts Q4 Earnings Beat, Upbeat Voxzogo Sales

by Zacks Equity Research

BioMarin (BMRN) reports encouraging fourth-quarter results, with earnings and sales beating estimates. The rapid uptake of Voxzogo boosts revenues.

Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

Intra-Cellular (ITCI) reports mixed fourth-quarter 2023 results despite Caplyta sales rising year over year on the back of increasing prescription trends.

Moderna (MRNA) Beats on Q4 Earnings & Sales, Reiterates View

by Zacks Equity Research

Moderna (MRNA) beats expectations for earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.

United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates

by Zacks Equity Research

United Therapeutics' (UTHR) fourth-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.

Bristol Myers' (BMY) Krazati sNDA for CRC Gets Priority Review

by Zacks Equity Research

Bristol Myers (BMY) announces FDA's acceptance of the sNDA seeking approval for the Krazati/Erbitux combo therapy to treat CRC patients. A final decision is expected on Jun 21, 2024.

Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Has Adicet Bio (ACET) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Adicet (ACET) Stock Rallies 130% in a Month: Here's Why

by Zacks Equity Research

Adicet (ACET) skyrockets 130% on a corporate update provided by the company discussing strategic priorities for 2024.

Adicet Bio, Inc. (ACET) Upgraded to Buy: Here's Why

by Zacks Equity Research

Adicet Bio, Inc. (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Are Medical Stocks Lagging Adicet Bio (ACET) This Year?

by Zacks Equity Research

Here is how Adicet Bio, Inc. (ACET) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.

Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus

by Zacks Equity Research

Editas' (EDIT) third-quarter 2023 results reflect a year-over-year increase in revenues. The stock of the company rises 18%.